Skip to main content

Advertisement

Advertisement

Pfizer, BioNTech seek US authorisation of Covid-19 booster shot for younger kids

WASHINGTON — Pfizer and its partner BioNTech SE said on Tuesday (April 26) that they had submitted an application to the United States (US) health regulator for the authorisation of a booster dose of their Covid-19 vaccine for children aged 5 to 11 years.

Pfizer, BioNTech seek US authorisation of Covid-19 booster shot for younger kids

Pfizer and BioNTech have filed for the clearance of a 10-microgram booster dose for children 5 to 11 years. Adults receive a 30-microgram dose of the vaccine.

WASHINGTON — Pfizer and its partner BioNTech SE said on Tuesday (April 26) that they had submitted an application to the United States (US) health regulator for the authorisation of a booster dose of their Covid-19 vaccine for children aged 5 to 11 years.

The companies earlier this month reported data from a mid-to-late stage study showing a third dose of their shot increased protection against the original coronavirus version and the Omicron variant among children in the age group.

It is unclear how much demand there is for a third vaccine dose in the age group. Just 28 per cent of children aged 5 to 11 years — around 8.2 million — are fully vaccinated, according to data from the US Centres for Disease Control and Prevention.

There has also been some scepticism on the need for boosters in younger children given the reduced risk of severe infection and hospitalization in the age group.

Pfizer and BioNTech have filed for the clearance of a 10-microgram booster dose for children 5 to 11 years. Adults receive a 30-microgram dose of the vaccine.

The primary two-dose Covid-19 shot from Pfizer and BioNTech was authorised in the United States for children 5 to 11 years in October.

The US Food and Drug Administration (FDA) in January authorised the use of a third dose of the companies' Covid-19 vaccine for children ages 12 to 15. The agency has also authorized a booster shot for children aged 5 through 11 years who are immunocompromised.

Rival Moderna is still waiting for a decision from US regulators on the use of its primary Covid-19 series among age groups under 18 years.

It plans to submit an application to the FDA for the authorization of its Covid-19 vaccine among kids six months to five years by the end of April. REUTERS

Related topics

Covid-19 coronavirus vaccination Pfizer-BioNTech Booster Shot

Read more of the latest in

Advertisement

Popular

Advertisement

Stay in the know. Anytime. Anywhere.

Subscribe to get daily news updates, insights and must reads delivered straight to your inbox.

By clicking subscribe, I agree for my personal data to be used to send me TODAY newsletters, promotional offers and for research and analysis.

Aa